cyc 202 has been researched along with rgb 286638 in 3 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (rgb 286638) | Trials (rgb 286638) | Recent Studies (post-2010) (rgb 286638) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 5 | 1 | 4 |
| 979 | 7 | 393 | 8 | 0 | 8 |
| Protein | Taxonomy | cyc 202 (IC50) | rgb 286638 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.001 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.003 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.002 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.002 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0025 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.001 | |
| Cyclin-H | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.002 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Giordano, A; Morales, F | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Duan, Y; Han, J; Hou, S; Liao, C; Wang, Q; Xie, Z; Yang, X | 1 |
2 review(s) available for cyc 202 and rgb 286638
| Article | Year |
|---|---|
Overview of CDK9 as a target in cancer research.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Flavonoids; Humans; Indolizines; Molecular Targeted Therapy; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridinium Compounds; Roscovitine; Thiazoles; Urea | 2016 |
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Discovery; Humans; Neoplasms; Protein Kinase Inhibitors | 2022 |
1 other study(ies) available for cyc 202 and rgb 286638
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |